AlphaRx Regains Rights to Indaflex(TM)
HONG KONG, June 29 /PRNewswire-FirstCall/ – AlphaRx, Inc. (OTCBB:ALRX) today announced that it has entered into an agreement with Cypress Bioscience (Nasdaq:CYPB – News), under which AlphaRx is regaining all rights to Indaflex(TM) from Cypress Bioscience, which AlphaRx had previously licensed to Proprius Pharmaceuticals, which was subsequently acquired by Cypress Bioscience.
“With our Cypress colleagues, we [...]
AlphaRx Provides Update on Indaflex
Hong Kong, May 10, 2010 (MARKETWIRE) — AlphaRx, Inc. (OTCBB: ALRX), has been advised by Cypress Biosciences (“Cypress”), its development partner for Indaflex, that Cypress is not funding development of Indaflex. Notwithstanding the termination of all Indaflex activity in the U.S.A., AlphaRx continues to develop Indaflex for the Chinese market. AlphaRx is working diligently with [...]
AlphaRx Plans to List Subsidiary
Companies need to periodically consider actions that unlock their intrinsic value. At this point in time, AlphaRx is pursuing such an opportunity.
Hong Kong, March 29, 2010 (MARKETWIRE) — AlphaRx, Inc. (OTCBB: ALRX) today announced that the Company plans to list its’ Canadian subsidiary, which has been focused on China and emerging markets, on a Canadian [...]
AlphaRx and Gaia BioPharma Secure Phase I/II Manufacturer for GAI-122 and Unveil Their Clinical Development Strategy
HONG KONG — (MARKET WIRE) — 01/21/10 AlphaRx Inc. (OTCBB: ALRX) announced today that its licensee, Gaia BioPharma Limited, has signed an agreement with a contract manufacturing organization (CMO) to manufacture GAI-122 for use in the planned Phase I and II clinical trials of that product candidate. GAI-122 is being developed as I.V. administered formulation [...]
AlphaRX – Review January 2010
After trading as high as $0.19 late last July the stock traded down to $0.07 on Dec. 7. During the dying days of 2009 the stock has traded wildly in a $0.075 to $0.16 range and closed out the year at $0.12. As much as I would like to offer a definitive opinion on [...]
AlphaRx’s Newly Appointed President of China Operations Unveils Strategic Corporate Initiatives
HONG KONG — (MARKET WIRE) — 12/21/09
AlphaRx Inc.’s (OTCBB: ALRX) recently appointed President of China Operations, Ruby Hui, today announced new corporate initiatives and the company’s strategic growth plan for China.
“When I was appointed as the President of AlphaRx China Operations a week ago, I promised that I would play a major part in AlphaRx’s [...]
AlphaRx Signs Contract Manufacturing Agreement for ARX1088
Hong Kong – December 17, 2009 – AlphaRx Inc. (OTCBB: ALRX) announced today that it has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other emerging markets. Under the agreement, Venturepharm will be [...]
